Tissue Regenix Group PLC

Tissue Regenix building its capabilities for future sustainable delivery

Steve Couldwell, chief executive of Tissue Regenix Group PLC (LON:TRX), caught up with Proactive's Andrew Scott to discuss the group's interim 2018 results.

In the six months to the end of June they inked distribution agreements with Arthrex and ARMS Medical of the US and Pennine Healthcare here in the UK.

Another milestone was British regulatory sign-off for the BioRinse portfolio, while manufacturing of DermaPure, the company’s wound care product, has been successfully transferred to the CellRight facility in Texas  ahead of schedule.

Couldwell says they've identified a number of potential new commercial opportunities they are “actively pursuing”.

Quick facts: Tissue Regenix Group PLC

Price: £0.03

Market: AIM
Market Cap: £39.26 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...



Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016


Unaudited Interim Results

1 week, 5 days ago

Appointment of CFO

3 weeks, 4 days ago

Directorate Change

on 08/01/2019

Holding(s) in Company

on 07/08/2019

Result of AGM

on 06/27/2019

Notice of AGM

on 06/04/2019

2 min read